cardiodiagnosticsinc.com (CDIO): Price-to-Projected Revenue Ratio

Cardio Diagnostics Holdings, Inc. - graphic logo of issuer CDIO

Cardio Diagnostics is implementing precision EpiCheck AI algorithms for autonomous epigenetic DNA analysis. This chart in the GURU.Markets terminal displays the forward P/S indicator, which has captured the metric at 278.00. The company's US-based retail business model minimizes geopolitical risks, although Cardio Diagnostics faces a fierce battle for insurance provider recognition within the growing digital diagnostics sector.

Cardio Diagnostics Holdings - CDIO Market Cap to Projected Revenue (period 11/15/2023 - 11/13/2026)

CDIO (cardiodiagnosticsinc.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Cardio Diagnostics Holdings|CDIO - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Cardio Diagnostics Holdings, Inc.|CDIO - Value Adjusted for Debt and Cash
- book value of equity indicators:
Book Value per Share Cardio Diagnostics|CDIO - Accounting Capitalization|Market Capitalization to Book Value Ratio cardiodiagnosticsinc.com|CDIO - Company Total Asset Base
- debt and solvency information:
Debt to Equity Cardio Diagnostics|CDIO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Cardio Diagnostics Holdings|CDIO - Aggregate Debt Obligations|Debts to Book Capitalization Cardio Diagnostics Holdings, Inc.|CDIO - Company Long-Term Indebtedness|Company Short-Term Debts Cardio Diagnostics|Quick Ratio cardiodiagnosticsinc.com
- financial results and valuation multiples details:
CDIO - Net Profit|Projected Future Earnings Cardio Diagnostics|CDIO - Market Cap to Net Income Ratio|Future Price to Earnings Cardio Diagnostics Holdings|CDIO - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cardio Diagnostics Holdings, Inc.|CDIO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Cardio Diagnostics|CDIO - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months cardiodiagnosticsinc.com|CDIO - Net earnings per one share growth for the current year|Earnings growth forecast for next year Cardio Diagnostics
- sales and revenue indicators:
CDIO - Company Gross Revenue|Projected Sales Volume Cardio Diagnostics Holdings|CDIO - Market Cap to Revenue|Price-to-Projected Revenue Ratio Cardio Diagnostics Holdings, Inc.
Summary company analysis:Cardio Diagnostics Holdings, Inc. CDIO
Original product of Cardio Diagnostics Holdings Inc.

Forward P/S relates current market capitalization to expected revenue, allowing for a business valuation relative to future cash flows while filtering out market noise. For Cardio Diagnostics (CDIO), this indicator reflects the scaling pace of genetic test sales within preventive medicine clinics, while the forward P/S trend helps determine whether the market price is fair relative to the actual growth in demand for cardiac diagnostics.

Competitor analysis for Cardio Diagnostics

Forward P/S Multiple A (Agilent)|Forward P/S Multiple Quest Diagnostics Inc. DGX|ILMN - Price-to-Projected Revenue Ratio|Forward Price to Sales EXAS (Exact Sciences Inc.)|RVTY: Forward P/S Multiple|Market Cap to Projected Revenue BIO|NNNN (Anbio) - Forward P/S Multiple|Sotera Health Corp (SHC) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio QuidelOrtho Corp (QDEL)|OPK - Market Cap to Future Revenue Ratio|CareDx, Inc - Forward Price-to-Revenue Multiple|Forward Price to Sales MRVI|Fulgent Genetics - Forward P/S Multiple|LAB (Standard BioTools Inc) - Market Cap to Projected Revenue|CTKB: Forward P/S Multiple|OSUR - Market Cap to Expected Sales Ratio|XGN (Exagen Inc) - Forward P/S Multiple|Forward P/S Multiple mdxhealth.com|Forward P/S Multiple LUCD|prenetics.com (PRE) - Projected Price to Revenue|Price-to-Projected Revenue Ratio Insight Molecular Diagnostics Inc IMDX|TRIB: Market Cap to Projected Revenue|PRPH - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio ainos.com|Co-Diagnostics (CODX) - Price-to-Projected Revenue Ratio|HSCS - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BMRA|ONCO (Onconetix Corporation) - Price to Expected Revenue Ratio|Forward P/S Multiple VRAX|Market Cap to Expected Sales Ratio bluejaydx.com|Forward P/S Multiple AWH (Aspira Women's Health Inc.)|AXDX - Forward Price-to-Revenue Multiple|CNTG - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Enzo Biochem, Inc. ENZ|FRES: Forward P/S Multiple|Forward Price-to-Revenue Multiple Genetic Technologies Limited|ME (23andMe) - Forward P/S Multiple|Market Cap to Projected Revenue PMD (Psychemedics Corp.)